Article

Optimal Clinical Trials Platform for Progressive Multiple Sclerosis (OCTOPUS): protocol for an international, multi-arm, multi-stage, platform, randomized controlled, double-blind, phase 3 clinical trial

2026-06-16

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Introduction</h4> Current treatments for multiple sclerosis (MS) do not address the pathological processes of neurodegeneration and chronic demyelination. This, coupled with the significant challenges of translating promising phase 2 results to phase 3 trial success, highlights the need for more efficient trial designs, such as platform multi-arm multi-stage (MAMS) trial approaches. MAMS tr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0a245c96-d7b0-5487-b59c-6dc5a0a6baae
DOI: 10.64898/2026.06.15.26355245

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Optimal Clinical Trials Platform for Progressive Multiple Sclerosis (OCTOPUS): protocol for an international, multi-arm, multi-stage, platform, randomized controlled, double-blind, phase 3 clinical trialDOI 10.64898/2026.06.15.26355245Read

MultiSCRIPT-Cycle 1- A Pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in Multiple Sclerosis: a study protocol for a randomized clinical trialSemantic proximity Read

Systematic Living Evidence for Clinical Trials (SyLECT): a data-driven framework for drug selection in clinical trials in motor neuron diseaseSemantic proximity Read

The Austrian MS Database and the Austrian MS Cohort – a national effort towards data harmonization and prospective data collectionSemantic proximity Read

Disease‑Modifying Trials in Parkinson’s Disease: Challenges, Lessons, and Future DirectionsSemantic proximity Read

Core protocol development for phase 2/3 clinical trials in the leukodystrophy Vanishing White MatterSemantic proximity Read

A master protocol to investigate a novel therapy acetyl-l-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasiaSemantic proximity Read

Metabolomic Signatures of Brain Atrophy and Ibudilast Response in Progressive Multiple SclerosisSemantic proximity Read

Disease stages and therapeutic hypotheses in two decades of neurodegenerative disease clinical trialsSemantic proximity Read

Quantifying MS Progression in the Era of Highly Effective Therapy: Trial Design ImplicationsSemantic proximity Read

Progressive MS: from pathophysiology to drug discoverySemantic proximity Read

From Fragmented Evidence to a Unified GCC Demyelinating Disease Registry: A Strategic Framework for MS, NMOSD, MOGAD, Optic Neuritis, LETM, and Pediatric Acquired DemyelinationSemantic proximity Read

FutureMS Cohort Profile: A Scottish Multi-Centre Inception Cohort Study of Relapsing-Remitting Multiple SclerosisSemantic proximity Read